Coupling Between Genome Translation and Replication in an RNA Virus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Xfect™ RNA Transfection Reagent Protocol-At-A-Glance
Xfect™ RNA Transfection Reagent Protocol-At-A-Glance I. Introduction A. Summary This Protocol-At-A-Glance is provided for transfection of cells with RNA using the Xfect RNA Transfection Reagent (Cat. No. 631450). It describes transfection of mammalian cells with RNA (mRNA, sgRNA, microRNA, or shRNA) in a 12-well plate format. For formats other than 12-well plates, see Tables I and II for appropriate reaction volumes. Transfections can be carried out entirely in the presence of serum. The protocol is divided into two sections: Section II describes transfection of cells with RNA only, without the cotransfection of DNA. Section III describes cotransfection of cells with both RNA and DNA. NOTE: When transfecting cells with mRNA, expression may be increased by using serum-free medium during transfection, since serum may contain RNases that can reduce the amount of full-length mRNA. B. General Considerations Storage & handling Store the Xfect RNA Transfection Polymer at –20°C. Do not thaw until ready to use. Once thawed, store at 4°C for up to 12 months. NOTE: The Xfect RNA Transfection Polymer is a milky suspension and should be vortexed briefly prior to use to ensure that it is fully resuspended. Thaw Xfect Reaction Buffer at room temperature just prior to use. Vortex after thawing. Once thawed, store Xfect Reaction Buffer at 4°C for up to 12 months. Xfect Polymer The protocol for cotransfection with DNA (Section III) requires the use of the Xfect Polymer (not included; sold as part of the DNA Xfect Transfection Reagent, Cat. Nos. 631317, 631318). -
Mrna Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
International Journal of Molecular Sciences Review mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection 1, 1, 2 1,3, Shuqin Xu y, Kunpeng Yang y, Rose Li and Lu Zhang * 1 State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China; [email protected] (S.X.); [email protected] (K.Y.) 2 M.B.B.S., School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; [email protected] 3 Shanghai Engineering Research Center of Industrial Microorganisms, Shanghai 200438, China * Correspondence: [email protected]; Tel.: +86-13524278762 These authors contributed equally to this work. y Received: 30 July 2020; Accepted: 30 August 2020; Published: 9 September 2020 Abstract: Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been widely proven as a promising treatment strategy in immune therapeutics. The extraordinary advantages associated with mRNA vaccines, including their high efficacy, a relatively low severity of side effects, and low attainment costs, have enabled them to become prevalent in pre-clinical and clinical trials against various infectious diseases and cancers. Recent technological advancements have alleviated some issues that hinder mRNA vaccine development, such as low efficiency that exist in both gene translation and in vivo deliveries. mRNA immunogenicity can also be greatly adjusted as a result of upgraded technologies. In this review, we have summarized details regarding the optimization of mRNA vaccines, and the underlying biological mechanisms of this form of vaccines. Applications of mRNA vaccines in some infectious diseases and cancers are introduced. It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis. -
2019 Annual Report
BECKMAN CENTER 279 Campus Drive West Stanford, CA 94305 650.723.8423 Stanford University | Beckman Center 2019 Annual Report Annual 2019 | Beckman Center University Stanford beckman.stanford.edu 2019 ANNUAL REPORT ARNOLD AND MABEL BECKMAN CENTER FOR MOLECULAR AND GENETIC MEDICINE 30 Years of Innovation, Discovery, and Leadership in the Life Sciences CREDITS: Cover Design: Neil Murphy, Ghostdog Design Graphic Design: Jack Lem, AlphaGraphics Mountain View Photography: Justin Lewis Beckman Center Director Photo: Christine Baker, Lotus Pod Designs MESSAGE FROM THE DIRECTOR Dear Friends and Trustees, It has been 30 years since the Beckman Center for Molecular and Genetic Medicine at Stanford University School of Medicine opened its doors in 1989. The number of translational scientific discoveries and technological innovations derived from the center’s research labs over the course of the past three decades has been remarkable. Equally remarkable have been the number of scientific awards and honors, including Nobel prizes, received by Beckman faculty and the number of young scientists mentored by Beckman faculty who have gone on to prominent positions in academia, bio-technology and related fields. This year we include several featured articles on these accomplishments. In the field of translational medicine, these discoveries range from the causes of skin, bladder and other cancers, to the identification of human stem cells, from the design of new antifungals and antibiotics to the molecular underpinnings of autism, and from opioids for pain -
Journal of Virology Volume 68 * April 1994 * Number 4
JOURNAL OF VIROLOGY VOLUME 68 * APRIL 1994 * NUMBER 4 Arnold J. Levine, Editor in Chief (1994) Vincent R. Racaniello, Editor (1997) Princeton University Columbia University Princeton, N.J. Peter M. Howley, Editor (1998) New York, N.Y Harvard Medical School John M. Coffin, Editor (1996) Boston, Mass. Thomas E. Shenk, Editor (1994) Tufts University Medical School Princeton University Boston, Mass. Michael B. A. Oldstone, Editor (1994) Princeton, N.J. Scripps Clinic & Research Foundation Ronald C. Desrosiers, Editor (1998) La Jolla, Calif. Joseph Sodroski, Editor (1998) Harvard Medical School Dana-Farber Cancer Institute Boston, Mass. Carol Prives, Editor (1996) Boston, Mass. Columbia University Mary K. Estes, Editor (1998) New N.Y Inder M. Verma, Editor (1998) Baylor College of Medicine York, The Salk Institute Houston, Tex. San Diego, Calif. EDITORIAL BOARD Rafi Ahmed (1994) Harry B. Greenberg (1995) Elizabeth Moran (1996) Priscilla A. Schaffer (1996) Carl C. Baker (1994) Hidesaburo Hanafusa (1995) Bernard Moss (1995) Heinz Schaller (1995) Amiya K. Banerjee (1996) Ed Harlow (1996) Richard W. Moyer (1995) Sondra Schlesinger (1995) Kenneth L. Berns (1994) Gary S. Hayward (1996) James Mullins (1996) Robert J. Schneider (1994) Joseph B. Bolen (1994) Ari H. Helenius (1996) Brian R Murphy (1994) Manfred H. Schubert (1996) Thomas J.'Braciale (1994) Virginia S. Hinshaw (1996) Nicholas A. Muzyczka (1996) Bartholomew M. Sefton (1994) John Brady (1994) David D. Ho (1996) Gerald Myers (1995) Bert L. Semler (1995) Thomas R. Broker (1995) James M. Hogle (1994) Gary J. Nabel (1996) David A. Shafritz (1994) Michael J. Buchmeier (1995) John J. Holland (1996) Opendra Narayan (1994) Yosef Shaul (1995) Robert Callahan (1994) Kathryn V. -
Poliovirus Mutant That Does Not Selectively Inhibit Host Cell Protein Synthesis
MOLECULAR AND CELLULAR BIOLOGY. November 1985. p. 2913-2923 Vol. 5. No. 11 0270-7306/85/112913-11$02.00/0 Copyright © 1985. American Society for Microbiology Poliovirus Mutant That Does Not Selectively Inhibit Host Cell Protein Synthesis HARRIS D. BERNSTEIN,1 NAHUM SONENBERG.~ AND DAVID BALTIMOREh Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, 1 and Department of Biochemistry, McGill Unirersity, Montreal, Quebec, Canada H3G I Y6~ Received 20 May 1985/Accepted 1 August 1985 A poliovirus type I (Mahoney strain) mutant was obtained by inserting three base pairs into an infectious eDNA clone. The extra amino acid encoded by the insertion was in the amino-terminal (protein 8) portion of the P2 segment of the polyprotein. The mutant virus makes small plaques on HeLa and monkey kidney (CV-1) cells at all temperatures. It lost the ability to mediate the selective inhibition of host cell translation which ordinarily occurs in the first few hours after infection. As an apparent consequence, the mutant synthesizes far less protein than does wild-type virus. In mutant-infected CV-1 cells enough protein was produced to permit a normal course of RNA replication, but the yield of progeny virus was very low. In mutant-infected He La cells there was a premature cessation of both cellular and viral protein synthesis followed by a premature halt of viral RNA synthesis. This nonspecific translational inhibition was distinguishable from wild-type-mediated inhibition and did not appear to be part of an interferon or heat shock response. -
Malaria Parasites Both Repress Host CXCL10 and Use It As a Cue for Growth Acceleration
ARTICLE https://doi.org/10.1038/s41467-021-24997-7 OPEN Malaria parasites both repress host CXCL10 and use it as a cue for growth acceleration Yifat Ofir-Birin 1, Hila Ben Ami Pilo1, Abel Cruz Camacho1, Ariel Rudik1, Anna Rivkin1, Or-Yam Revach1, Netta Nir1, Tal Block Tamin1, Paula Abou Karam1, Edo Kiper1, Yoav Peleg2, Reinat Nevo1, Aryeh Solomon3, Tal Havkin-Solomon1, Alicia Rojas1, Ron Rotkopf 4, Ziv Porat 5, Dror Avni6,7, Eli Schwartz6,7, Thomas Zillinger 8, Gunther Hartmann 8, Antonella Di Pizio 9, Neils Ben Quashie 10,11, Rivka Dikstein1, Motti Gerlic12, Ana Claudia Torrecilhas 13, Carmit Levy14, Esther N. M. Nolte-‘t Hoen15, ✉ Andrew G. Bowie 16 & Neta Regev-Rudzki 1 1234567890():,; Pathogens are thought to use host molecular cues to control when to initiate life-cycle transitions, but these signals are mostly unknown, particularly for the parasitic disease malaria caused by Plasmodium falciparum. The chemokine CXCL10 is present at high levels in fatal cases of cerebral malaria patients, but is reduced in patients who survive and do not have complications. Here we show a Pf ‘decision-sensing-system’ controlled by CXCL10 concentration. High CXCL10 expression prompts P. falciparum to initiate a survival strategy via growth acceleration. Remarkably, P. falciparum inhibits CXCL10 synthesis in monocytes by disrupting the association of host ribosomes with CXCL10 transcripts. The underlying inhi- bition cascade involves RNA cargo delivery into monocytes that triggers RIG-I, which leads to HUR1 binding to an AU-rich domain of the CXCL10 3’UTR. These data indicate that when the parasite can no longer keep CXCL10 at low levels, it can exploit the chemokine as a cue to shift tactics and escape. -
Efficient Sirna Delivery and Gene Silencing Using a Lipopolypeptide Hybrid Vector Mediated by a Caveolae-Mediated and Temperatur
Kasai et al. J Nanobiotechnol (2019) 17:11 https://doi.org/10.1186/s12951-019-0444-8 Journal of Nanobiotechnology RESEARCH Open Access Efcient siRNA delivery and gene silencing using a lipopolypeptide hybrid vector mediated by a caveolae‑mediated and temperature‑dependent endocytic pathway Hironori Kasai1, Kenji Inoue1, Kentaro Imamura1,2, Carlo Yuvienco3, Jin K. Montclare3,4,5,6 and Seiichi Yamano1* Abstract Background: We developed a non-viral vector, a combination of HIV-1 Tat peptide modifed with histidine and cysteine (mTat) and polyethylenimine, jetPEI (PEI), displaying the high efciency of plasmid DNA transfection with lit- tle toxicity. Since the highest efciency of INTERFERin (INT), a cationic amphiphilic lipid-based reagent, for small inter- fering RNA (siRNA) transfection among six commercial reagents was shown, we hypothesized that combining mTat/ PEI with INT would improve transfection efciency of siRNA delivery. To elucidate the efcacy of the hybrid vector for siRNA silencing, β-actin expression was measured after siRNA β-actin was transfected with mTat/PEI/INT or other vec- tors in HSC-3 human oral squamous carcinoma cells. Results: mTat/PEI/INT/siRNA produced signifcant improvement in transfection efciency with little cytotoxicity com- pared to other vectors and achieved 100% knockdown of β-actin expression compared to non-treated cells. The electric charge of mTat/PEI/INT/siRNA≈ was signifcantly higher than INT/siRNA. The particle size of mTat/PEI/INT/siRNA was signifcantly smaller than INT/siRNA. Filipin III and β-cyclodextrin, an inhibitor of caveolae-mediated endocyto- sis, signifcantly inhibited mTat/PEI/INT/siRNA transfection, while chlorpromazine, an inhibitor of clathrin-mediated endocytosis, did not inhibit mTat/PEI/INT/siRNA transfection. -
Interference Interfering RNA-Mediated RNA Inhibition Of
Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference John Capodici, Katalin Karikó and Drew Weissman This information is current as J Immunol 2002; 169:5196-5201; ; of September 29, 2021. doi: 10.4049/jimmunol.169.9.5196 http://www.jimmunol.org/content/169/9/5196 Downloaded from References This article cites 27 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/169/9/5196.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2002 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference1 John Capodici,* Katalin Kariko´,† and Drew Weissman2* RNA interference (RNAi) is an ancient antiviral response that processes dsRNA and associates it into a nuclease complex that identifies RNA with sequence homology and specifically cleaves it. -
Microbiology and Immunology (MI) Courses” Section of This Assistants for Two Courses
National Science Foundation. Program for Graduate Study—The Ph.D. degree requires course MICROBIOLOGY AND work and independent research demonstrating an individual’s creative, scholastic, and intellectual abilities. On entering the department, students meet an advisory faculty member; together they IMMUNOLOGY design a timetable for completion of the degree requirements. Typically, this consists of first identifying gaps in the student’s Emeriti: (Professors) Edward S. Mocarski, Sidney Raffel, Leon T. undergraduate education and determining courses that should be Rosenberg taken. Then, a tentative plan is made for two to four lab rotations Chair: Karla Kirkegaard (one rotation per quarter). During the first year of graduate study in Associate Chair: Hugh O. McDevitt the department, each student also takes six or seven upper-level Professors: Ann Arvin, Helen Blau, John C. Boothroyd, Yueh-Hsiu (200-series) courses. Three of these courses are requirements of the Chien, Mark M. Davis, Stanley Falkow, Stephen J. Galli, Harry department: MI 215, Principles of Biological Techniques; MI 209, B. Greenberg, Karla Kirkegaard, A. C. Matin, Hugh O. Advanced Pathogenesis of Bacteria, Viruses, and Eukaryotic McDevitt, Peter Parham, Phillip Pizzo, Charles Prober, David Parasites, Part I; and MI 210, Advanced Pathogenesis of Bacteria, Relman, Peter Sarnow, Gary K. Schoolnik, Lucy S. Tompkins Viruses, and Eukaryotic Parasites, Part II. Three courses are part of Associate Professors: Christopher Contag, Garry Nolan, David the core curriculum that is required of many graduate students in Schneider, Julie Theriot Stanford Biosciences: BIO 203 /DBIO 203 /GENE 203, Advanced Assistant Professors: Manuel Amieva, Matthew Bogyo, Chang- Genetics; BIO 230, Molecular and Cellular Immunology; and MCP Zheng Chen, Denise Monack, Upinder Singh, Justin Sonnenburg, 221/BIO 214, Cell Biology of Physiological Processes. -
Method for Efficient Transfection of in Vitro-Transcribed Mrna Into SK-N-AS and HEK293 Cells: Difference in the Toxicity of Nuclear EGFP Compared to Cytoplasmic EGFP
1011-1016 2/5/06 13:15 Page 1011 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 17: 1011-1016, 2006 Method for efficient transfection of in vitro-transcribed mRNA into SK-N-AS and HEK293 cells: Difference in the toxicity of nuclear EGFP compared to cytoplasmic EGFP KATARINA EJESKÄR1,2, SUSANNE FRANSSON2, FATEN ZAIBAK1 and PANAYIOTIS A. IOANNOU1 1Murdoch Children's Research Institute, Melbourne University, Royal Children's Hospital, 3052 Parkville, VIC, Australia; 2Department of Clinical Genetics, Göteborg University, SU/Östra, SE-416 85 Gothenburg, Sweden Received December 2, 2005; Accepted January 20, 2006 Abstract. Here we report a method for efficient transfection Introduction of in vitro-transcribed mRNA into two different types of human adherent cells, the neuroblastoma cell line SK-N-AS, A major challenge today is to analyze the functions of many and the transformed kidney cell line HEK293. By using newly genes at the cellular level (1). It is possible to conduct high- trypsinized adherent cells in suspension and Lipofectamine™ throughput screening through transfectional microarrays (2) 2000, we detected a transfection efficiency of 80-90% in both but, for many research groups, this is not an option because it cell lines and a cell viability of 90% in SK-N-AS and 60% in requires costly equipment and, for many research projects, it HEK293, 24 h after transfection when using cytoplasmic might not be necessary to test thousands of genes. enhanced green fluorescent protein (EGFP)-mRNA. We have The major issue in functional gene studies in living cells evaluated the different effects of the generally used EGFP that is good transfection efficiency, and there are numerous different mainly localizes to the cytoplasm and nuclear EGFP, where the methods for DNA/RNA delivery available, all with advantages nuclear EGFP are more toxic to the cells than the cytoplasmic and drawbacks (3). -
Lecture Slides
(J. American Chemical Association, 78, 3458-3459) The Secondary Structure of Complementary RNA E. Peter Geiduschek, John W. Moohr, and Smauel B. Weiss, Proceedings of The National Academy of Sciences, 48, 1078-1086, 1962. R.H. DOI RH, and S. SPIEGELMAN Homology test between the nucleic acid of an RNA virus and the DNA in the host cell. Science 1962 Dec 14 1270-2. MONTAGNIER L, SANDERS FK. REPLICATIVE FORM OF ENCEPHALOMYOCARDITIS VIRUS RIBONUCLEIC ACID. Nature. 1963 Aug 17;199:664-7. (Science 143, 1034-1036, March 6, 1964) WARNER RC, SAMUELS HH, ABBOTT MT, KRAKOW JS. (1963) Ribonucleic acid polymerase of Azotobacter vinelandii, II. Formation of DNA- RNA hybrids with single-stranded DNA as primer. Proc Natl Acad Sci U S A. 49:533-8. Double Stranded RNA as a Specific Biological Effector December 8, 2006 Karolinska Institute, Stockholm, Sweden Viral interference (Interferon) effects in animals M. Hoskins (1935) A protective action of neurotropic against viscerotropic yellow fever virus in Macacus rhesus. American Journal of Tropical Medicine, 15, 675-680 G. Findlay and F. MacCallum (1937) An interference phenomenon in relation to yellow fever and other viruses. J. Path. Bact. 44, 405-424. A. Isaacs and J. Lindenmann (1957) Virus Interference. I. The Interferon Proc. Royal Soc. B 147, 268-273. Proceedings of the National Academy of Sciences, USA, Volume 58, Pages 782-789. 1967 Promoter Make transgenic worms geneX Antisense Transcripts Interference (Development 113:503 [1991]) geneX Promoter Make transgeneic worms geneX SENSE Transcripts Also Interference! (Development 113:503 [1991]) In Vitro Promoter Make RNA in vitro geneX Antisense RNA Inject worm gonad Interference! (Guo and Kemphues, 1995) In Vitro geneX Promoter Make RNA in vitro geneX SENSE RNA Inject worm gonad Also Interference! (Guo and Kemphues, 1995) Craig Mello's RNAi Workshop: 1997 C. -
Surrender, Avoidance and Subversion by Microorganisms
REVIEWS CELLULAR AUTOPHAGY: SURRENDER, AVOIDANCE AND SUBVERSION BY MICROORGANISMS Karla Kirkegaard, Matthew P.Taylor and William T. Jackson Intracellular bacteria and viruses must survive the vigorous antimicrobial responses of their hosts to replicate successfully. The cellular process of autophagy — in which compartments bound by double membranes engulf portions of the cytosol and then mature to degrade their cytoplasmic contents — is likely to be one such host-cell response. Several lines of evidence show that both bacteria and viruses are vulnerable to autophagic destruction and that successful pathogens have evolved strategies to avoid autophagy, or to actively subvert its components, to promote their own replication. The molecular mechanisms of the avoidance and subversion of autophagy by microorganisms will be the subject of much future research, not only to study their roles in the replication of these microorganisms, but also because they will provide — as bacteria and viruses so often have — unique tools to study the cellular process itself. 6,7 4 DAUER Cellular autophagy involves the sequestration of thaliana and C. elegans ,wild-type autophagy genes An arrested stage in regions of the cytosol within double-membrane-bound are required to prevent premature senescence. Caenorhabditis elegans compartments that then mature and degrade their cyto- One attractive hypothesis is that the degradation of development that can be formed plasmic contents. It is a highly regulated process, the cytosolic structures by autophagy might have